Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of atypical emerging pneumonia. The clinical spectrum varies from an asymptomatic or mild illness to a serious illness with a high risk of mortality. The most severely affected patients (5%) present an acute respiratory distress syndrome (ARDS), requiring assistance with mechanical ventilation in intensive care. In 2003, persistent lung damage was observed in a third of patients in a Singaporean cohort one year after SARS-CoV infection. A Chinese study showed that 27.3% of their SARS-CoV patients presented a decreased carbon monoxide diffusion (DLCO) and 21.5% of pulmonary fibrosis lesions. Due to the very recent emergence of SARS-CoV-2, no data is currently available of long-term outcome of these patients. However, recent publications including short-term CT monitoring suggest the genesis of fibrotic pulmonary parenchymal sequelae. In view of these data, the investigators can fear the occurrence of pulmonary sequelae in patients infected with SARS-CoV-2. It is therefore essential to evaluate the evolution of the respiratory status of the most severe patients who have had a stay in intensive care with respiratory assistance.
Diagnostic Test: Pulmonary function testing
D0: date of first symptoms of SARS-COV-2
M3: D0 + 3 months
Blood test
Blood gases
Clinical examination
CT Scan
Pulmonary function testing (PFT)
6-minute walk test (6MWT)
MOS SF-36 Questionnaire
HADS scale
Ventilatory polygraphy
M6: D0 + 6 months
Clinical examination
PFT
6MWT
MOS SF-36 Questionnaire
HADS scale
M12: D0 + 12 months
Blood test
Blood gases
Clinical examination
CT Scan (If anomaly found at M3)
PFT
Pulmonary Exercise Stress Test
6MWT
MOS SF-36 Questionnaire
HADS scale
Subsequent follow-up will be performed only in patients with an alteration defined by a DLCO
Clinical examination
PFT
6MWT
MOS SF-36 Questionnaire
HADS scale
Other Name: Array
Inclusion Criteria:
- Patient infected by SARS-CoV-2 (diagnosed by RT-PCR and / or typical CT imaging)
- Patient hospitalized in the intensive care units of Besançon or Dijon hospitals for
severe SARS-CoV-2 pneumonia
- Postmenopausal woman for at least 24 months or surgically sterilized, or, for woman of
childbearing age, use of an effective method of contraception
- Signature of informed consent to participate indicating that the subject has
understood the purpose and the procedures required by the study and that he agrees to
participate in the study.
- Affiliation to a French social security system .
Exclusion Criteria:
- Chronic respiratory failure under long-term oxygen therapy
- Known diffuse invasive pneumonia
- Life expectancy estimated at less than one year by the doctor
- Legal incapacity or limited legal capacity
- History of psychiatric illness, intellectual disability, lack of motivation or other
conditions that may limit the understanding of informed consent
- Subject unlikely to cooperate in the study and / or weak cooperation anticipated by
the investigator
- Subject without health insurance
- Pregnant and / or lactating woman
- Subject being in the exclusion period of another study or foreseen by the "national
file of the volunteers".
CHU Besançon
Besançon, Franche-Comté, France